Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

243 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial.
Boyle MP, Bell SC, Konstan MW, McColley SA, Rowe SM, Rietschel E, Huang X, Waltz D, Patel NR, Rodman D; VX09-809-102 study group. Boyle MP, et al. Among authors: konstan mw. Lancet Respir Med. 2014 Jul;2(7):527-38. doi: 10.1016/S2213-2600(14)70132-8. Epub 2014 Jun 24. Lancet Respir Med. 2014. PMID: 24973281 Clinical Trial.
Inflammatory cytokines in cystic fibrosis lungs.
Bonfield TL, Panuska JR, Konstan MW, Hilliard KA, Hilliard JB, Ghnaim H, Berger M. Bonfield TL, et al. Among authors: konstan mw. Am J Respir Crit Care Med. 1995 Dec;152(6 Pt 1):2111-8. doi: 10.1164/ajrccm.152.6.8520783. Am J Respir Crit Care Med. 1995. PMID: 8520783
Cystic fibrosis.
Davis PB, Drumm M, Konstan MW. Davis PB, et al. Among authors: konstan mw. Am J Respir Crit Care Med. 1996 Nov;154(5):1229-56. doi: 10.1164/ajrccm.154.5.8912731. Am J Respir Crit Care Med. 1996. PMID: 8912731 Review. No abstract available.
Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center study.
Noone PG, Hamblett N, Accurso F, Aitken ML, Boyle M, Dovey M, Gibson R, Johnson C, Kellerman D, Konstan MW, Milgram L, Mundahl J, Retsch-Bogort G, Rodman D, Williams-Warren J, Wilmott RW, Zeitlin P, Ramsey B; Cystic Fibrosis Therapeutics Development Research Group. Noone PG, et al. Among authors: konstan mw. Pediatr Pulmonol. 2001 Aug;32(2):122-8. doi: 10.1002/ppul.1098. Pediatr Pulmonol. 2001. PMID: 11477729 Clinical Trial.
Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.
Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N, Accurso F, Dovey M, Hiatt P, Konstan MW, Moss R, Retsch-Bogart G, Wagener J, Waltz D, Wilmott R, Zeitlin PL, Ramsey B; Cystic Fibrosis Therapeutics Development Network Study Group. Gibson RL, et al. Among authors: konstan mw. Am J Respir Crit Care Med. 2003 Mar 15;167(6):841-9. doi: 10.1164/rccm.200208-855OC. Epub 2002 Dec 12. Am J Respir Crit Care Med. 2003. PMID: 12480612 Clinical Trial.
243 results